Recommended ART Regimen for Patients with CLD and AKI
For HIV patients with both chronic liver disease and acute kidney injury, use abacavir/lamivudine/dolutegravir as the preferred single-tablet regimen, avoiding tenofovir-based regimens and ritonavir-boosted protease inhibitors entirely.
Primary Regimen Selection
The combination of abacavir/lamivudine/dolutegravir represents the optimal choice because:
- No renal dose adjustment required: Dolutegravir requires no dose modification even with CrCl <30 mL/min, though close monitoring is advised 1
- Proven safety in severe renal impairment: This regimen achieved 83% viral suppression in ESRD patients on hemodialysis with excellent tolerability 2
- Hepatically metabolized: Avoids additional renal toxicity burden during AKI recovery
- Single-tablet convenience: Improves adherence in complex medical situations
Critical Drugs to Avoid
Absolutely Contraindicated:
- Tenofovir disoproxil fumarate (TDF): Causes cumulative nephrotoxicity with 1-2% developing treatment-limiting tubulopathy; associated with eGFR decline and proteinuria 3. TDF-based regimens should be discontinued when CrCl <50 mL/min 1
- Ritonavir-boosted protease inhibitors (atazanavir, lopinavir): Linked to rapid eGFR decline, incident CKD, and interstitial nephritis 3. These agents increase tenofovir exposure and compound nephrotoxicity risk 3
Use With Extreme Caution:
- Tenofovir alafenamide (TAF): While safer than TDF, should still be avoided when CrCl <30 mL/min 4
- Elvitegravir/cobicistat combinations: Must be discontinued when CrCl <50 mL/min 1
Alternative Regimens by Renal Function
For CrCl >30 mL/min:
- First choice: Abacavir/lamivudine/dolutegravir
- Alternative: Raltegravir 400 mg twice daily (no dose adjustment needed) plus abacavir/lamivudine 1
For CrCl <30 mL/min or Hemodialysis:
- Abacavir/lamivudine/dolutegravir remains preferred 2
- Raltegravir requires no adjustment even in ESRD 1
- Maraviroc can be used at 300 mg twice daily, reduced to 150 mg twice daily if orthostatic hypotension occurs; avoid with CYP3A4 inhibitors 1
Monitoring Requirements
Given the dual organ dysfunction:
- Baseline assessment: Document CrCl, eGFR, proteinuria, and liver function tests before ART initiation 3
- Early monitoring: Check renal function at 2-4 weeks, then monthly during AKI recovery
- Watch for AKI progression: 14% of AKI cases in HIV patients progress to CKD, particularly those with worse baseline renal function 5
- Liver parameter surveillance: Comorbid liver tumors (aOR 18.89) and hypertension (aOR 4.25) increase risk of abnormal liver parameters during treatment 6
Common Pitfalls to Avoid
Cotrimoxazole interaction: Concomitant use is associated with increased AKI risk and can falsely elevate creatinine through tubular secretion competition 5. Consider this when interpreting renal function changes.
Misattributing eGFR decline: TDF initiation causes significant eGFR decline (-6.45 mL/min/1.73 m² at 1 year) that may be mistaken for disease progression 5
Underestimating structural damage: AKI in the setting of liver disease often involves structural kidney injury, making it less responsive to volume repletion and vasopressors 7. This necessitates nephrotoxin avoidance rather than relying on supportive measures alone.
Delayed regimen switching: If a patient is already on TDF or ritonavir-boosted PIs, immediate switching to abacavir/lamivudine/dolutegravir is associated with improved kidney function 3
Hepatic Considerations
While dolutegravir and abacavir are hepatically metabolized, they remain safe in CLD when liver synthetic function is preserved. The primary concern is monitoring for drug-induced liver injury, particularly in patients with:
- Pre-existing liver tumors
- Hypertension
- Metabolic dysfunction-associated steatotic liver disease 6
The key principle: Prioritize renal-sparing agents during AKI while maintaining virologic efficacy, as immune control reduces both AKI incidence and HIV-related kidney disease progression 3.